N-Terminal Region of Gelsolin Induces Apoptosis of Activated Hepatic Stellate Cells by a Caspase-Dependent Mechanism

Budhaditya Mazumdar¹, Keith Meyer¹, Ranjit Ray¹,² *

¹ Department of Internal Medicine, Saint Louis University, St. Louis, Missouri, United States of America, ²Department of Molecular Microbiology and Immunology, Saint Louis University, St. Louis, Missouri, United States of America

Abstract
Activated hepatic stellate cells (HSCs) are the major source for alteration of extracellular matrix in fibrosis and cirrhosis. Conditioned medium (CM) collected from immortalized human hepatocytes (IHH) have earlier been shown to be responsible for apoptosis of HSCs. In this study, we have shown that antibodies raised against a peptide derived from a linear B-cell epitope in the N-terminal region of gelsolin identified a gelsolin fragment in IHH CM. Analysis of activated stellate cell death by CM collected from Huh7 cells transfected with plasmids encoding gelsolin deletion mutants suggested that the N-terminal half of gelsolin contained sequences which were responsible for stellate cell death. Further analysis determined that this activity was restricted to a region encompassing amino acids 1–70 in the gelsolin sequence; antibody directed to an epitope within this region was able to neutralize stellate cell death. Gelsolin modulation of cell death using this fragment involved upregulation of TRAIL-R1 and TRAIL-R2, and involved caspase 3 activation by extrinsic pathway. The apoptotic activity of N-terminal gelsolin fragments was restricted to activated but not quiescent stellate cells indicating its potential application in therapeutic use as an anti-fibrotic agent. Gelsolin fragments encompassing N-terminal regions in polypeptides of different molecular sizes were detected by N-terminal peptide specific antiserum in IHH CM immunoprecipitated with chronically HCV infected patient sera, suggesting the presence of autoantibodies generated against N-terminal gelsolin fragments in patients with chronic liver disease.

Introduction
HSCs are located in perisinusoidal space which contains several extracellular matrix (ECM) molecules, such as type I, III, IV, V and VI collagens, laminin, fibronectin and proteoglycans [1,2]. ECM molecules are recognized as the primary cellular source of matrix components in chronic liver disease, and therefore play a critical role in the development and maintenance of liver fibrosis [3]. In quiescent state, HSCs have a low mitotic activity and are mainly responsible for the uptake, storage and delivery of retinoids [4]. However, in response to liver injury conditions, these cells undergo an activation process to transform into proliferative, fibrogenic, proinflammatory, and contractile myofibroblasts which express α-smooth muscle actin (α-SMA) [4]. These activated stellate cells secrete extracellular matrix protein type I collagen that is associated with the development of liver fibrosis and cirrhosis [5,6]. Hepatic fibrosis is reversible [7–9], and its resolution requires the loss of activated HSCs via apoptosis [7,8,10].

We studied the functional relationship between IHH generated by the introduction of HCV core gene into primary human hepatocytes, and human hepatic stellate cells (LX2) spontaneously generated as immortalized phenotype in cell culture. Apoptosis of activated LX2 cells occurred in the presence of CM from IHH [11]. Further studies suggested that IHH CM increased the expression of TRAIL receptors on LX2 cell surface and induced apoptosis by a caspase dependent mechanism. Peptide mass fingerprinting of a purified soluble mediator from CM indicated that gelsolin fragments may play a role in LX2 apoptosis [11]. Gelsolin, an ~83 KD calcium-binding protein, is involved in the remodeling of cellular actin filaments associated with cell shape changes and movement. Gelsolin interacts with actin in a Ca²⁺-dependent manner and weakens noncovalent bonds between actin filaments to make them susceptible to cleavage [12,13]. Gelsolin sequence contains six structurally homologous domains (S1 through S6) of 120–130 amino acids that appear to have originated from gene triplication of the prototypical domain followed by gene duplication [14,15]. Hence, gelsolin is composed of two domains (the N-terminal S1–S3 and the C-terminal S4–S6 halves) separated by a 70 amino acid linker sequence, which is cleaved by different proteases [16–18].

Besides playing an important role in remodeling of actin filaments inside cells, gelsolin is also secreted from several mammalian cell types into blood. Originally defined by its interactions with actin, this secretory form, now called plasma gelsolin, circulates in mammalian blood at concentrations of...
200–300 µg/ml [19–22]. Human plasma gelsolin differs from the cytoplasmic isoform by an additional sequence of 24 amino acids, designated as the “plasma extension” signal that remains in the mature protein after cleavage of the peptide that directs plasma gelsolin to the secretory pathway into the endoplasmic reticulum, where plasma gelsolin folds and a disulfide bond is formed [23,24]. Liver has been suggested to be a major source of plasma gelsolin and human hepatoma cell line HepG2 produces and secretes plasma gelsolin [23]. Plasma gelsolin acts as an actin-scavenging protein to prevent increases in blood viscosity caused by considerable amounts of actin that are released from dying cells during inflammatory processes, especially during acute lung injury [25]. A single amino acid mutation in domain 2 (S2) of plasma gelsolin (D187N/Y) affects Ca²⁺ binding and folding of plasma gelsolin [26]. This leads to aberrant cleavage of the misfolded protein in the trans-Golgi, generating a secretory 60 kD fragment of the protein (C66) [27,28]. C66 can be further cleaved into smaller fragments by extracellular proteases like MT1-MMP [29] to generate major (8 kD) and minor (5 kD) amyloidogenic fragments that form extracellular membranous deposits on various muscle as well as non-muscle tissues [30,31].

Over-expression of the Ca²⁺ independent severing N-terminal half of gelsolin induces apoptosis, whereas gelsolin null neutrophils have a delayed onset of apoptosis [16]. In this study, we have identified the N-terminal region comprising of amino acids 1–70 in the gelsolin sequence as responsible for apoptotic cell death of activated HSCs involving an upregulation of TRAIL-R1 and TRAIL-R2 and activation of caspase 3 by extrinsic pathway.

Materials and Methods

Cells

IHII were generated by transfection of a plasmid DNA expressing HCV core genomic region of genotype 1a (Genbank accession number M62321) into primary human hepatocytes under the control of a CMV promoter [32,33]. LX2 cells [11,34] was used in this study and grown in Dulbecco’s modified Eagle medium (DMEM), supplemented with 10% fetal bovine serum and 2X L-glutamine. Human hepatoma (Huh7) cells were grown in DMEM, supplemented with 10% fetal bovine serum and antibiotics. Cell proliferation was detected using a CellTiter 96 Aqueous non-radioactive cell proliferation assay (Promega, Madison, WI), following supplier’s protocol. LX2 cells were grown on Matrigel (BD Biosciences) when necessary to maintain the quiescent phenotype.

Gelsolin

A cDNA encoding human gelsolin was procured (Origene). Purified gelsolin from human plasma was purchased (Sigma, St. Louis).

Cloning and expression of N-terminal gelsolin fragments

Human plasma gelsolin cDNA (encompassing amino acids 1–782) was cloned into a N-terminal FLAG-bearing pCMV vector (D1) that was subcloned by restriction digestion to yield plasmid DNA constructs encoding N-terminal (1–450) (D2) and C-terminal (450–782) (D3) fragments. Plasmids encoding smaller N-terminal fragments (1–70; D2-F1) (1–130; D2-F2) and (70–450; D2-F3) were further subcloned from the plasmid encoding larger FLAG-tagged (1–450; D2) fragment using digestion by specific restriction enzymes followed by ligation. Plasmid DNAs were introduced into Huh 7 cells by transfection using lipofectamine for protein expression.

Preparation of conditioned medium (CM)

IHII were grown on a collagen type I coated on plastic plate in small airway epithelial cell growth medium (SAGM) supplemented with 5% chemically denatured fetal bovine serum at 37°C. At ~90% confluency, cells were washed and incubated in serum free SAGM for 48 h. CM was clarified by centrifugation at 6,000 g to remove cell debris, supplemented with 2X L-glutamine, and stored at −20°C until use.

Antibody generation

Chicken antisera were generated from predicted N-terminal linear B-cell epitopes and evaluated for characterization of reactivity with gelsolin. Antisera were purified and used in subsequent experiments for detection of N-terminal gelsolin fragment. The antisera G1 and G2 raised against two peptides derived from N-terminal region of gelsolin (representing amino acids 35–50: CSQAGAPQGVPAREPN, and 75–93: CKFDLVPVPTNYGDFFITGD, respectively) differed in their reactivity against IHII CM by Western blot analysis.

Protein expression

Western blot analysis was performed to analyze the activation levels of caspases-9 and 3 using specific monoclonal antibodies (R&D Systems, Minneapolis, MN). CM from IHII or CHO cells transfected with plasmids encoding specific gelsolin fragments were incubated with anti-TRAIL-R1, anti-TRAIL-R2 (R & D Systems) or isotype specific antibodies (negative controls), followed by FITC-conjugated secondary antibody for fluorescence-activated cell-sorter (FACS) analysis. Non-specific background was determined from untreated and isotype matched unrelated negative control antibodies. Positive cells were identified by FACScan (Beckton Dickinson), and results analyzed using Cell Quest software. Ten thousand cells were analyzed for each sample and gating was set on the basis of a dot plot for 90˚ light scatter versus forward angle light scatter to exclude dead cells and debris from analysis.

Results

Identification of N-terminal gelsolin fragments in conditioned medium from hepatocyte cultures

Previous reports indicated that immunoprecipitation of IHII CM, responsible for apoptotic activity towards HSCs, with sera from chronic liver patients followed by Western blotting with a gelsolin specific monoclonal antibody GS-2C4 (Sigma) directed to the C-terminal half of the protein, revealed several cleaved fragments presumably originating from gelsolin (ranging from 30 kD to 65 kD) [11]. It is likely that the N-terminal half of the protein, reported to possess apoptotic activity [16] will escape detection by this antibody. In order to detect the N-terminal half in gelsolin fragments present in CM, chicken antibodies G1 and G2 were generated that were directed to peptides derived from two adjacent regions (amino acid residues 35–50 and 75–93, respectively) in the N-terminal half of gelsolin. Western blot analysis suggested that these two antibodies differed in their reactivity to IHII CM resulting in different band patterns (Fig. 1, panel A). Full-length gelsolin was detected by both the antibodies. However, only G1 antibody could detect the ~60 kD gelsolin fragment in IHII CM. Gelsolin fragments were also identified in CM by Western blot using gelsolin G1 antibody after immunoprecipitation with sera from patients with chronic hepatitis (Fig. 1, panel B). Gelsolin antibody G1 was subsequently used for detection of gelsolin fragments in this study.
Figure 1. Presence of N-terminal gelsolin fragments in hepatocyte conditioned medium. Panel A: Western blot of CM with chicken antibodies raised against peptides (G1 and G2) selected from the N-terminal region of gelsolin. Purified gelsolin from human plasma was included as a positive control in the experiment. SAGM medium, used for culture of stellate cells, was used as a negative control. (B) Immunoprecipitation of CM with healthy control and chronically HCV infected patient sera, followed by Western blotting with chicken anti-gelsolin antibody G1. The positions of protein molecular weight markers (kD) are shown on the left.

doi:10.1371/journal.pone.0044461.g001

Figure 2. Effect of CM from Huh 7 cells transfected with gelsolin fragments on LX2 growth. Panel A: CM from Huh7 cells transfected with plasmid constructs- D2 encoding N-terminal half (amino acids 1–450) and D3 encoding C-terminal half (amino acids 450–782) displayed distinct LX2 cell viability. LX2 cells treated with IHH CM as a positive control and untreated LX2 as a negative control were included in the experiment. Cell viability was determined from triplicate culture wells by a CellTiter 96 Aqueous non-radioactive cell proliferation assay (Promega) at different time points and presented as mean and standard deviations. Panel B: LX2 cell viability following incubation with CM from Huh7 cells transfected with deletion mutants encoding gelsolin fragments (amino acids 1–450, 1–70, 1–130 and 70–450) were similarly determined. Effect of medium (untreated) and IHH CM treated positive controls were included for comparison. Cell viability was determined from triplicate culture wells by a CellTiter 96 Aqueous non-radioactive cell proliferation assay (Promega) at different time points and presented as mean and standard deviations. Panel C: Expression of gelsolin N-terminal 1–70 fragment in CM from 293T cells transfected with FLAG-tagged D2–F1 construct. CM from transfected cells was immunoprecipitated with anti-FLAG antibody and analyzed by Western blot using anti-gelsolin G1 antibody. CM from mock-transfected 293T cells served as negative control.

doi:10.1371/journal.pone.0044461.g002
Stellate cell death associates with N-terminal region of gelsolin

Conditioned medium from Huh7 cells transfected with plasmid construct D2 encoding N-terminal half of gelsolin sequence (amino acids 1–450) induced rapid human hepatic stellate cell death as determined using a Cell proliferation assay kit (Promega). However, stellate cell death was not detectable when incubated with CM from Huh7 cells transfected with plasmid construct D3 encoding gelsolin C-terminal half (amino acids 450–782) (Fig. 2, panel A). Conditioned medium from non-transfected Huh7 cells acted as a negative control, and did not cause a detectable stellate cell death. Next, we compared the ability of differently-sized N-terminal gelsolin fragments to cause stellate cell death. Conditioned medium collected from Huh7 cells after introduction of either one of the two smaller N-terminal gelsolin fragments- D2–F1 (1–70) or D2–F2 (1–130) showed marginally stronger stellate cell death activity compared to the larger D2 fragment (1–450) fragment from which they are derived with the 1–70 being the

Figure 3. Antibody to N-terminal fragment of gelsolin antagonizes LX2 cell death. CM from IHH (panel A) or from Huh 7 cells transfected with N-terminal gelsolin fragments consisting of amino acids 1–70, 1–130 and 70–450 (panel B) was preincubated with immobilized gelsolin G1 or TRAIL antibody, and subsequently tested for LX2 cell growth. Effect of normal medium (untreated) and CM without preincubation were included for comparison. Cell viability was determined from triplicate culture wells by a CellTiter 96 Aqueous non-radioactive cell proliferation assay (Promega) at different time points and presented as mean and standard deviations.

doi:10.1371/journal.pone.0044461.g003
most potent among the three of them (Fig. 2, panel B). On the other hand, CM collected from Huh7 cells after introduction of gelsolin fragment D2–F3 (70–450) did not cause an appreciable difference in stellate cell death as compared to untreated control indicating that stellate cell death activity of IHH CM could be restricted to 1–70 region in gelsolin sequence. For the purpose of detecting smaller gelsolin fragments in CM from cells transfected with corresponding gene constructs, 293T cells were transfected with the N-terminal FLAG-tagged D2–F1 construct that encodes gelsolin sequence 1–70. CM was collected, immunoprecipitated with anti-FLAG antibody, and subsequently detected using antigelosin G1 antibody. The gelsolin fragment was detected as a ~7 kD band (Fig. 2, panel C). 293T cells were chosen over Huh7 cells for this purpose because of consistently higher levels of expression and detection of gelsolin fragments in these cells after transfection of corresponding gene constructs.

N-terminal gelsolin fragment mediated stellate cell death is antagonized by peptide specific antibody

We have shown previously that CM utilizes the TRAIL signaling pathway to induce apoptosis [11]. Initial microscopic observations suggested that onset of stellate cell death by IHH CM is delayed for about 24 h after incubation with immobilized anti-gelsolin G1 antibody. This was further examined by quantifying LX2 cell death after adding CM with or without neutralization with the anti-gelsolin G1 antibody as well as anti-TRAIL antibody over a 72 h time period. For this, the antibodies were immobilized on Protein G Sepharose beads, and CM was incubated with the immobilized antibody. The suspension was centrifuged to separate the beads, filter sterilized, and added to LX2 cells for apoptotic cell death. LX2 cell viability was significantly affected after 24 h in presence of IHH CM. On the other hand, viability was restored to almost similar levels as that in untreated controls when CM was preincubated with G1 antibody (Fig. 3, panel A). On the other hand, neutralization with anti-TRAIL antibody did not cause any significant inhibition of the ability of IHH CM in stellate cell death. Next, we determined G1 antibody specific antagonism of LX2 cell death after incubation of CM from Huh 7 cells transfected with multiple N-terminal gelsolin fragments consisting of amino acids 1–70, 1–130 and 70–450 respectively. Inhibition of stellate cell death was observed by the G1 antibody against fragments of gelsolin encompassing the amino acid residues 1–70, and 1–130; as well as the fragment derived from gelsolin containing supernatant (Fig. 3, panel B). Thus, the experiments with N-terminal specific antibodies validated the role of gelsolin in IHH CM-mediated LX2 stellate cell death.

Figure 4. Induction of TRAIL receptors by N-terminal region in gelsolin fragments. FACS analysis was performed to determine the expression levels of TRAIL-R1 (panel A) and TRAIL-R2 (panel B) on LX2 cell surface treated with CM from Huh 7 cells transfected with gelsolin fragments 1–70 (dark green line), 1–450 (orange line) and 450–782 (red line). Expression of these proteins in cells treated with media (blue line) was included as control. Cells were either treated with specific monoclonal antibody or isotype control antibody (light green line), followed by treatment with FITC-conjugated secondary antibody for FACS analysis. doi:10.1371/journal.pone.0044461.g004

N-terminal gelsolin fragment induces TRAIL-R1 and TRAIL-R2 expression on stellate cell surface

Previous studies using FACS analyses indicated that IHH CM mediated stellate cell death involves significant upregulation of TRAIL-R1 and TRAIL-R2 expression on cell surface [11]. In this study, we used FACS analysis for TRAIL-R1 and TRAIL-R2 expression on stellate cells exposed to CM containing gelsolin deletion mutants to determine whether this upregulation was mediated by the N-terminal region of gelsolin fragments present in CM. We observed that upregulation of both TRAIL-R1 (Fig. 4, panel A) and TRAIL-R2 (Fig. 4, panel B) by CM from Huh 7 cells transfected with constructs encoding the N-terminal half of gelsolin sequence (1–450) as well as smaller N-terminal (1–70) fragment. The C-terminal half of gelsolin (450–782) did not cause an induction of TRAIL-R expression.
N-terminal gelsolin fragment induces caspase-3 mediated apoptotic death in activated LX2 cells

Activated LX2 cells, when grown on Matrigel-coated plate, tend to revert to the quiescent phenotype. In order to achieve quiescent state, stellate cells were grown on Matrigel and microscopically monitored for a change in appearance. The quiescent state of the stellate cells was also examined by staining for desmin and smooth muscle actin (SMA) by Western blotting. These protein markers were absent or present at a very low level in quiescent state, and their levels dramatically enhanced upon activation following growth on plastic surface. Quiescent LX2 cells on Matrigel were incubated with IHH CM and cell viability was assayed by the cell proliferation assay kit (Promega). Unlike activated LX2 cells, quiescent LX2 cell death was not observed in the presence of IHH CM, even after 3 days (Fig 5, panel A). This observation was further supported by unchanged procaspase 3 levels in quiescent LX2 cells that were incubated with IHH CM compared to those in media control (Fig. 5, panel B). On the other hand, a significant reduction in procaspase-3 expression in activated LX2 cells was observed when incubated with IHH CM. Thus, our results suggested that activated - but not quiescent- stellate cells undergo apoptosis in the presence of IHH CM. Interestingly, caspase 3 activation was decreased when activated stellate cells were incubated with IHH CM previously treated with immobilized anti-gelsolin G1 antibody (Fig. 5, panel C). The results validate that apoptotic activity of IHH CM upon stellate cells is directed by the N-terminal region in gelsolin present in the CM. Apoptosis of activated stellate cells in IHH CM did not involve procaspase 9 activation (Fig. 5, panel D), indicating that the intrinsic pathway is not involved in the process.

Discussion

Quiescent stellate cells undergo activation to adopt myofibroblast morphology and secrete type I collagen, the principal matrix protein responsible for the development of liver fibrosis and cirrhosis under pathological conditions. Our previous report has shown that conditioned medium from IHH caused apoptosis of activated stellate cells, and gelsolin was implicated as an active component in IHH CM [11]. In this study, we have shown that...
the apoptotic activity of gelsolin resides in the N-terminal region present in the S1 domain. We have investigated the possible mechanism of action for apoptotic activity of gelsolin fragment and have further shown the involvement of TRAIL-R1 and R2 upregulation and activation of caspases 3 by the extrinsic pathway. Fragments derived from gelsolin sequence have been identified previously in IHH CM by immunoprecipitation followed by Western blot analysis using commercially available gelsolin monoclonal antibody GS-2C4, directed to its C-terminal half [11]. However, this antibody recognizes an epitope containing a C-terminal actin binding site, and failed to deplete gelsolin from CM or inhibit CM mediated LX2 apoptosis. To understand the gelsolin fragments responsible for CM mediated apoptotic activity towards LX2 cells, we developed an anti-gelsolin antibody that recognizes gelsolin fragments in Western blotting and immunoprecipitation, and also antagonizes CM-mediated LX2 apoptosis. N-terminal region of gelsolin comprising of first three homologous domains (S1–S3) has been previously shown to be apoptotic [16]. We generated chicken antibody G1 against a synthetic peptide derived from the region comprising amino acids 35–50 in the N-terminal half of gelsolin. Also, we performed subcloning of a construct encoding full-length gelsolin (amino acids 1–782) or smaller deletion mutants cloned into a pCMV mammalian expression vector. Quantitative estimation of stellate cell death mediated by CM from Huh7 cells transfected with the gelsolin fragments indicated higher apoptotic potential of the N-terminal half of gelsolin compared to the C-terminal half. Also, comparison of stellate cell killing activity among the N-terminal fragments revealed that the apoptotic activity displayed by gelsolin fragments was localized in the N-terminal region encoding amino acids 1–70.

Next, we investigated whether anti-peptide G1 antibody representing a B cell epitope of the N-terminal region of gelsolin antagonizes stellate cell death mediated by CM containing N-terminal gelsolin fragments 1–450 and 1–70 from transfected Huh7 cells. We observed a significant inhibition of stellate cell death by these N-terminal gelsolin fragments when CM was preincubated with this antibody indicating the functional significance of N-terminal gelsolin fragments. Previous studies [11] indicated that IHH CM mediated LX2 cell death involved upregulation of TRAIL-R1 and TRAIL-R2 on the cell surface. We observed a similar upregulation of TRAIL-R1 and TRAIL-R2 expression levels on LX2 cell surface upon exposure to CM from Huh7 cells containing N-terminal gelsolin fragments representing amino acid residues 1–450 or 1–70. Interestingly, TRAIL did not appear to act as a soluble mediator in the process as evident by the absence of TRAIL in CM by Western blotting as well as failure of anti-TRAIL antibody to effectively inhibit CM-mediated LX2 cell death. LX2 apoptosis by CM containing gelsolin fragments involved activation of procaspase 3 and inhibited to normal level when CM was incubated with anti-gelsolin G1 antibody, further indicating that N-terminal region of gelsolin fragments in CM leads to apoptosis of LX2 by caspase activation. Unaltered levels of procaspase 9 suggested that the apoptotic pathway involved the extrinsic route involving TRAIL receptor upregulation. The mechanism regulating gelsolin-mediated upregulation of TRAIL receptors in a TRAIL-independent manner is intriguing and is still largely unknown. Sequence homology or structural similarity between gelsolin and TRAIL were not observed to warrant a direct interaction between gelsolin and TRAIL receptors. There are also no reports for specific gelsolin receptors on cell membrane surfaces. Gelsolin is susceptible to cleavage to amyloidogenic fragments of sizes as small as 6–8 kDa that deposit on membranous surfaces of many tissues [29–31], and will be interesting to determine whether this phenomenon activates apoptotic pathway on the target cell.

Interestingly, apoptotic cell death by IHH CM, was directed to activated LX2 cells, but did not affect quiescent LX2 cells. Administration of gelsolin can be potentially employed as an agent to resolve fibrosis, characterized by death of activated stellate cells in a suitable animal model. In this study, we have provided evidence for induction of cell death by a generated fragment of gelsolin which mimics the activity apparent in stellate cells treated with CM from immortalized hepatic cell lines. Further studies should elucidate precise mechanism of cell death, and identify therapeutic potential of this gelsolin fragment as an anti-fibrotic agent.

Acknowledgments

We thank Peter Yaciuk for helping with the identification of potential B cell epitopes in gelsolin sequence, Scott Friedman for providing LX2 cells as gift, Ratna B. Ray, Sandip K. Bose, and Yie-Hwa Chang for technical suggestions, and Lin Cowick for preparation of the manuscript.

Author Contributions

Conceived and designed the experiments: RR. Performed the experiments: BM KM. Analyzed the data: BM KM RR. Wrote the paper: BM RR.

References

1. Martinez-Hernandez A (1984) The hepatic extracellular matrix. I. Electron immunohistotechnical studies in normal rat liver. Lab Invest 51:57–74.
2. Griffiths MR, Keir S, Burt AD (1991) Basement membrane proteins in the space of Disse: a reappraisal. J Clin Pathol 44:646–649.
3. Friedman SL (2000) Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275:2247–2250.
4. Geerts A (2001) History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 21:311–333.
5. Akolado R, Arthur MJ, Iredale JP (1997) Pathogenesis of liver fibrosis. Clin Sci (Lond) 92:103–112.
6. Fischer R, Schmitt M, Bode JG, Haussinger D (2001) Expression of the peripheral-type benzodiazepine receptor and apoptosis induction in hepatic stellate cells. Gastroenterology 120:1212–1226.
7. Iredale JP (2001) Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 21:427–436.
8. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, et al. (1998) Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 102:538–549.
9. Arthur MJ (2002) Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 122:1525–1528.
10. Anan A, Baskin-Bey ES, Bronk SF, Werneburg NW, Shah VH, et al. (2006) Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology 43:335–341.
11. Basu A, Saito K, Meyer K, Ray RB, Friedman SL, et al. (2006) Stellate cell apoptosis by a soluble mediator from immortalized human hepatocytes. Apoptosis 11:1391–1400.
12. Sun HQ, Yamamoto M, Mejillano M, Yin HL (1999) Gelsolin, a multifunctional actin regulatory protein. J Biol Chem 274:33179–33182.
13. Khlaifi n A, Hassan H (2002) Ca-dependent binding of actin to gelsolin. FEBS Lett 521:14–18.
14. Mishra VS, Hendske EP, Kwiatkowski DJ, Southwick FS (1998) The human actin- regulatory protein cap G: gene structure and chromosome location. Geronomics 23:560–563.
15. Arai M, Kwiatkowski DJ (1999) Differential developmentally regulated expression of gelsolin family members in the mouse. Dev Dyn 215:297–307.
16. Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, et al. (1997) Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 278:294–298.
17. Kamada S, Kasano H, Fujita H, Obata M, Koya RC, et al. (1998) A cloning method for caspase substrates that uses the yeast two-hybrid system: cloning of the antia apoptotic gene gelsolin. Proc Natl Acad Sci USA 95:8532–8537.
10. Ashish S, Paine MS, Perryman PB, Yang L, Yin HL, et al. (2007) Global structure changes associated with Ca$$^{2+}$$ activation of full-length human plasma gelsolin. J Biol Chem 282:25884–25892.
11. Janmey PA, Lind SE (1987) Capacity of human serum to depolymerize actin filaments. Blood 70:524–530.
12. Smith DB, Janmey PA, Herbert TJ, Lind SE (1987) Quantitative measurement of plasma gelsolin and its incorporation into fibrin clots. J Lab Clin Med 110:189–195.
13. Lind SE, Smith DB, Janmey PA, Stossel TP (1988) Depression of gelsolin levels and detection of gelsolin-actin complexes in plasma of patients with acute lung injury. Am Rev Respir Dis 138:429–434.
14. Kwiatkowski DJ, Mehl R, Izumo S, Nadal-Ginard B, Yin HL (1988) Muscle is the major source of plasma gelsolin. J Biol Chem 263:8239–8243.
15. Yin HL, Kwiatkowski DJ, Mele JE, Cole FS (1984) Structure and biosynthesis of cytoplasmic and secreted variants of gelsolin. J Biol Chem 259:5271–5276.
16. Zapun A, Grammatyka S, Deral G, Vernet T (2000) Calcium-dependent conformational stability of modules 1 and 2 of human gelsolin. Biochem J 350 (Pt 3):873–881.
17. Smith DB, Janmey PA, Lind SE (1988) Circulating actin-gelsolin complexes following oleic acid-induced lung injury. Am J Pathol 130:261–267.
18. Huff ME, Page LJ, Ralch WE, Kelly JW (2003) Gelsolin domain 2 Ca$$^{2+}$$ affinity determines susceptibility to furin proteolysis and familial amyloidosis of Finnish type. J Mol Biol 334:119–127.
19. Chen CD, Huff ME, Matteson J, Page L, Phillips R, et al. (2001) Furin initiates gelsolin familial amyloidosis in the Golgi through a defect in Ca$$^{2+}$$ stabilization. EMBO J 20:627–6287.
20. Kangas H, Seidah NG, Paunio T (2002) Role of proprotein convertases in the pathogenic processing of the amyloidosis-associated form of secretory gelsolin. Amyloid 9:83–87.
21. Page LJ, Suk JY, Huff ME, Lim HJ, Venable J, et al. (2005) Metalloendoprotease cleavage triggers gelsolin amyloidogenesis. EMBO J 24:412–4132.
22. Kiuru S (1998) Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide. Amyloid 5:5–66.
23. Kiuru-Enari S, Somer H, Seppahainen AM, Notkola II, Halstia M (2002) Neuromuscular pathology in hereditary gelsolin amyloidosis. J Neuropathol Exp Neurol 61:565–571.
24. Ray RB, Meyer K, Ray R (2000) Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology 271:197–204.
25. Basu A, Meyer K, Ray RB, Ray R (2002) Hepatitis C virus core protein is necessary for the maintenance of immortalized human hepatocytes. Virology 299:53–62.
26. Taimr P, Higuchi H, Kocova E, Rippe RA, Friedman S, et al. (2003) Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 37:87–95.